Denis E Ryono, Age 74100 3Rd St, Minneapolis, MN 55401

6395784, May 28, 2002

May 31, 2001

09/871347

Denis E. Ryono - Princeton NJ

Bristol-Myers Squibb Company - Princeton NJ

A01N 3712

514563, 514538, 514539, 560 39, 560 41, 562444, 562449, 562450

New thyroid receptor ligands are provided which have the general formula in which: X is —O—, —S—, —CH —, —CO—, or —NH—; R is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R and R are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R and R being other than hydrogen; R is methyl, ethyl, n-propyl or trifluoromethyl; R is hydrogen or lower alkyl; R is carboxylic acid, or esters or prodrugs; R is hydrogen or an alkanoyl or an aroyl. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

6800605, Oct 5, 2004

Jan 16, 2001

09/761050

Todd J. Friends - Hamilton NJ
Denis E. Ryono - Princeton NJ
Minsheng Zhang - Warren NJ

Bristol-Myers Squibb Company - Princeton NJ

C07C 3700

514 2, 514576, 514577, 514717, 514730, 514736, 568579, 568583, 568585, 568588, 568626, 568630, 568635

New thyroid receptor ligands are provided which have the general formula in which: X is —O—, —S—, —CH —, —CO—, or —NH—; Y is —(CH ) — where n is an integer from 1 to 5, or cis- or trans-ethylene; R is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R and R are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R and R being other than hydrogen; R is hydrogen or lower alkyl; R is hydrogen or lower alkyl; R is carboxylic acid, or esters or prodrugs; R is hydrogen or an alkanoyl or an aroyl. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

6989402, Jan 24, 2006

Dec 23, 1999

09/868889

Jon Hangeland - Morrisville PA, US
Minsheng Zhang - Warren NJ, US
Yolanda Caringal - Lawrenceville NJ, US
Denis Ryono - Princeton NJ, US
Yi-Lin Li - Huddinge, SE
Johan Malm - Skogas, SE
Ye Liu - Tullinge, SE
Neeraj Garg - Tumba, SE
Chris Litten - Tumba, SE
Ana Maria Garcia Collazo - Stockholm, SE
Konrad Koehler - Huddinge, SE

Karo Bio AB - Huddinge

A61K 31/44
A61K 31/192
A61K 31/40
A61K 31/4174
C07D 211/56
C07D 213/72
C07D 229/38
C07D 265/30
C07D 241/04
C07D 207/14

514563, 5142378, 514398, 514399, 544162, 544402, 546224, 546309, 5483714, 548567, 562444, 562449

New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; Ris halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; Rand Rare the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of Rand Rbeing other than hydrogen; Ris a carboxylic acid amide (CONR′R″) or an acylsulphonamide (CONHSO2R′) derivative, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof; or when n is equal to or greater than one, Rmay be a heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR′R″). Ris hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R=H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a Tregulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a Tregulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

7109164, Sep 19, 2006

Aug 30, 2004

10/930360

Todd J. Friends - Hamilton NJ, US
Denis E. Ryono - Princeton NJ, US
Minsheng Zhang - Warren NJ, US

Bristol-Myers Squibb Company - Princeton NJ

C07C 37/00

514 2, 514576, 514577, 514717, 514730, 514736, 568579, 568583, 568585, 568588, 568626, 568630, 568635

New thyroid receptor ligands are provided which have the general formulaIn addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a Tregulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a Tregulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

7153997, Dec 26, 2006

Jul 8, 2003

10/520902

Neeraj Garg - Tumba, SE
Mahmoud Rahimi Ghadim - Stockholm, SE
Thomas Anders Wilson Ericsson - Sodertawg, SE
Lars Johan Malm - Trangsund, SE
Denis Evan Ryono - Princeton NJ, US

Karo Bio AB - Huddinge
Bristol-Myers Squibb Company - Princeton NJ

C07C 229/08
A61K 31/195

562444, 562442, 562443, 562445, 562447, 514563

This invention relates to novel compounds, which are thyroid receptor ligands, and to methods of preparing such compounds. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described herein is administered in a therapeutically effective amount.

7288571, Oct 30, 2007

Jul 26, 2005

11/189654

Jon Hangeland - Morrisville PA, US
Minsheng Zhang - Warren NJ, US
Yolanda Caringal - Lawrenceville NJ, US
Denis Ryono - Princeton NJ, US
Yi-Lin Li - Huddinge, SE
Johan Malm - Skogas, SE
Ye Liu - Tullinge, SE
Neeraj Garg - Tumba, SE
Chris Litten - Tumba, SE
Ana Maria Garcia Collazo - Stockholm, SE
Konrad Koehler - Huddinge, SE

Karo Bio AB - Huddinge

A61K 31/18
C07C 311/50

514601, 514649, 564 80, 564336

New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; Ris halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; Rand Rare the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of Rand Rbeing other than hydrogen; Ris a carboxylic acid amide (CONR′R″) or an acylsulphonamide (CONHSOR′) derivative, or a pharmaceutically acceptable salt thereof, and all stereolsom thereof; or when n is equal to or greater than one, Rmay be heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR′R″). Ris hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R—H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependant upon the expression of a Tregulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a Tregulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

7342127, Mar 11, 2008

Jan 23, 2004

10/763878

William N. Washburn - Titusville NJ, US
Wei Meng - Pennington NJ, US
Denis E. Ryono - Princeton NJ, US
Bruce A. Ellsworth - Princeton NJ, US
Thomas Ericsson - Sodertalje, SE
Mahmoud Rahimi-Ghadim - Stockholm, SE
Neeraj Garg - Tumba, SE
Johan Malm - Trangsund, SE

Bristol-Myers Squibb Company - Princeton NJ
Karo Bio AB - Huddinge

C07C 54/00
C07C 315/00
C07C 229/00
A01N 37/12

562471, 562430, 562442, 562443, 514534

Novel thyroid receptor ligands are provided having the general formula IIn addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolic dysfunction or which are dependent upon the expression of a Tregulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

7557143, Jul 7, 2009

Apr 15, 2004

10/826100

Denis E. Ryono - Princeton NJ, US
Jon J. Hangeland - Morrisville PA, US
Todd J. Friends - Bordentown NJ, US
Tamara Dejneka - Skillman NJ, US
Pratik Devasthale - Plainsboro NJ, US
Yolanda V. Caringal - Lawrenceville NJ, US
Minsheng Zhang - Warren NJ, US
Arthur M. P. Doweyko - Long Valley NJ, US
Johan Malm - Trangsund, SE
Andrei Sanin - Varby, SE

Bristol-Myers Squibb Company - Princeton NJ

A61K 31/165
A61K 31/19
C07C 239/00
C07C 325/00
C07C 229/00
C07C 59/00

514568, 514617, 562426, 562433, 562452, 562465, 564161

Thyroid receptor ligands are provided which have the general formula IIn addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a Tregulated gene, wherein a compound as described above is administered in a therapeutically effective amount.